Artivion, Inc.

Valuation Analysis

About the Company

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent gra

Artivion, Inc. Stock at a Glance

Artivion, Inc. (AORT) is currently trading at $20.10 with a market capitalization of $975.7M. The trailing P/E ratio stands at 80.4x, with a forward P/E of 27.16x. The 52-week range spans from $19.16 to $48.25; the current price is 58.3% below the yearly high. Year-over-year revenue growth stands at +17.5%. The net profit margin stands at 2.55%.

💰 Dividend

Artivion, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

8 analysts rate Artivion, Inc. (AORT) on consensus: Strong Buy. The average price target is $42.00, implying +108.96% from the current price. Analyst price targets range from $36.00 to $48.00.

Artivion, Inc.: The Investment Case in Detail

Artivion, Inc. (AORT) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 17.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 64.55%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 108.96% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

With a net margin of just 2.55%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

At a PEG of 643.75, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

What to Watch Next

• The forward P/E of 27.16x is meaningfully below the trailing 80.4x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 108.96% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy Artivion, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.